It has been recently revealed in a report that the Food and Drug Administration has come up with an all new ‘biosimilar’ drugs. These drugs are actually much cheaper than the complex types usually available in the market. They are made from biological matter.

Some of these drugs are like cancer drug Herceptin, Remicade for rheumatoid arthritis, erythropoietin for anemia and so on. It was found that Erythropoietin alone puts a cost of $4 billion, on the shoulders of the government. These new guidelines by the FDA are made for the purpose of being able to put up a strong fight on huge medical costs that people are facing these days.

The FDA has set these new guidelines and all drug manufacturing companies shall be required to abide by these rules. They shall actually be required to start mid way in the manufacturing process and deal with the excessive costs, by making drugs that match the quality and standards of the previous ones, but with reduced price tags.

It has been said that the FDA action has come later, though the European Union has already adopted this policy. They already have a number of biosimilar drugs available in the market, for tacking the huge medical costs borne by people.

"There are so many unknowns commercially. We don't know what the competitive environment will look like. We don't know what the pricing will be. And there still is regulatory uncertainty”, said Scott Foraker, who heads Amgen's year-old biosimilar unit.

There is need for a middle way to be found by the authorities and the medical firms, which will together help in providing cheaper options for, medicines to people, without need for compromising with quality.